Subtopic Deep Dive
CYP2C19 Polymorphisms in Antiplatelet Therapy
Research Guide
What is CYP2C19 Polymorphisms in Antiplatelet Therapy?
CYP2C19 polymorphisms refer to genetic variations in the CYP2C19 enzyme that impair clopidogrel bioactivation, leading to reduced antiplatelet efficacy in cardiovascular patients.
Loss-of-function alleles *2 and *3 in CYP2C19 predict clopidogrel hyporesponsiveness and higher adverse cardiovascular events (Mega et al., 2008, 2431 citations). Guidelines recommend genotype-guided therapy selection in PCI patients (Scott et al., 2013, 942 citations). Over 10 key papers, including trials and meta-analyses, establish clinical impact.
Why It Matters
CYP2C19 testing guides switch from clopidogrel to prasugrel or ticagrelor in poor metabolizers post-PCI, reducing stent thrombosis by up to 30% (Claassens et al., 2019). Mega et al. (2008) showed carriers face 1.5-3x higher event rates. Scott et al. (2013) CPIC guidelines enable precision dosing, adopted in ESC updates (Valgimigli et al., 2017), improving outcomes in 20-30% of patients with loss-of-function alleles.
Key Research Challenges
Genotype-Clinical Outcome Correlation
Variability in CYP2C19 allele frequency across ethnicities complicates universal risk prediction (Mega et al., 2008). Trials show inconsistent event rate reductions with genotyping (Claassens et al., 2019). Meta-analyses needed for subgroup power.
Integration into PCI Guidelines
Guidelines like Levine et al. (2011) acknowledge polymorphisms but lack routine testing mandates due to cost-effectiveness data gaps. Kushner et al. (2009) updates highlight pharmacogenetic needs without firm recommendations. Implementation trials are sparse.
Drug Interaction Confounds
PPIs like omeprazole inhibit CYP2C19, mimicking poor metabolizer effects (Bhatt et al., 2010; Juurlink et al., 2009). Studies show increased reinfarction risk with PPI co-use (Juurlink et al., 2009, 763 citations). Disentangling genetic vs. drug effects requires adjusted models.
Essential Papers
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
Glenn N. Levine, Eric Bates, James C. Blankenship et al. · 2011 · Circulation · 3.3K citations
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
Marco Valgimigli, Héctor Bueno, Robert A. Byrne et al. · 2017 · European Heart Journal · 2.9K citations
International audience
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
Jessica L. Mega, Sandra Close, Stephen D. Wiviott et al. · 2008 · New England Journal of Medicine · 2.4K citations
Among persons treated with clopidogrel, carriers of a reduced-function CYP2C19 allele had significantly lower levels of the active metabolite of clopidogrel, diminished platelet inhibition, and a h...
2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update)
Frederick G. Kushner, Mary M. Hand, Sidney C. Smith et al. · 2009 · Circulation · 1.7K citations
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA
S. Claiborne Johnston, J. Donald Easton, Mary Farrant et al. · 2018 · New England Journal of Medicine · 1.3K citations
In patients with minor ischemic stroke or high-risk TIA, those who received a combination of clopidogrel and aspirin had a lower risk of major ischemic events but a higher risk of major hemorrhage ...
Clopidogrel with or without Omeprazole in Coronary Artery Disease
Deepak L. Bhatt, Byron Cryer, Charles F. Contant et al. · 2010 · New England Journal of Medicine · 1.2K citations
Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding. There was no apparent cardiovascular interaction between clopidogrel...
2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update)
Hani Jneid, Jeffrey L. Anderson, R. Scott Wright et al. · 2012 · Circulation · 1.1K citations
Reading Guide
Foundational Papers
Start with Mega et al. (2008) for core polymorphism-event link (2431 citations), then Scott et al. (2013) CPIC guidelines for therapy recommendations, followed by Levine et al. (2011) PCI guidelines integrating pharmacogenetics.
Recent Advances
Claassens et al. (2019) genotype-guided PCI trial (592 citations) shows noninferiority; Valgimigli et al. (2017) ESC DAPT update refines role.
Core Methods
Genotyping (TaqMan PCR for *2/*3); pharmacodynamics (VASP-PRI, VerifyNow); outcomes via Cox models on MACE (stent thrombosis, MI); CPIC dosing tiers.
How PapersFlow Helps You Research CYP2C19 Polymorphisms in Antiplatelet Therapy
Discover & Search
Research Agent uses searchPapers and citationGraph on 'CYP2C19*2 clopidogrel PCI' to map 250M+ OpenAlex papers, revealing Mega et al. (2008, 2431 citations) as hub with 100+ forward citations to trials like Claassens et al. (2019). exaSearch uncovers meta-analyses; findSimilarPapers expands to ethnic-specific allele studies.
Analyze & Verify
Analysis Agent applies readPaperContent to extract HRs from Mega et al. (2008), then verifyResponse with CoVe chain-of-verification cross-checks against Scott et al. (2013) guidelines. runPythonAnalysis computes pooled ORs from trial data via pandas, with GRADE grading for evidence quality in PCI outcomes.
Synthesize & Write
Synthesis Agent detects gaps like post-PCI implementation barriers via contradiction flagging between guidelines (Levine et al., 2011 vs. Claassens et al., 2019). Writing Agent uses latexEditText, latexSyncCitations for guideline tables, and latexCompile for publication-ready reviews; exportMermaid diagrams allele impact flowcharts.
Use Cases
"Run meta-analysis on CYP2C19 LOF alleles and MACE in clopidogrel PCI patients"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-regression on HRs from Mega 2008, Claassens 2019) → outputs forest plot CSV and GRADE-scored summary.
"Draft LaTeX review on genotype-guided DAPT post-PCI"
Synthesis Agent → gap detection → Writing Agent → latexEditText (structure sections) → latexSyncCitations (Mega 2008, Scott 2013) → latexCompile → researcher gets compiled PDF with synced bibtex.
"Find analysis code for CYP2C19 pharmacogenetics simulations"
Research Agent → paperExtractUrls (Scott 2013 supp) → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets R scripts for allele frequency modeling.
Automated Workflows
Deep Research workflow scans 50+ clopidogrel pharmacogenetic papers, chaining searchPapers → citationGraph → GRADE synthesis for systematic review reports on *2/*3 impact. DeepScan's 7-step analysis verifies PPI interactions (Bhatt 2010) with CoVe checkpoints and Python hazard ratios. Theorizer generates hypotheses on multi-allele scoring from Mega (2008) literature.
Frequently Asked Questions
What defines CYP2C19 loss-of-function polymorphisms?
Alleles *2 and *3 reduce CYP2C19 enzyme activity, impairing clopidogrel to active metabolite conversion (Mega et al., 2008; Scott et al., 2013).
What methods test CYP2C19 genotype-response?
Genotyping via PCR identifies *2/*3; platelet function assays (VerifyNow) measure inhibition; RCTs compare event rates (Claassens et al., 2019).
What are key papers?
Mega et al. (2008, NEJM, 2431 citations) links alleles to events; Scott et al. (2013) CPIC guidelines; Claassens et al. (2019) genotype-guided RCT.
What open problems remain?
Cost-effectiveness of routine testing; polygenic risk beyond *2/*3; PPI-genotype interaction modeling in diverse populations.
Research Antiplatelet Therapy and Cardiovascular Diseases with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching CYP2C19 Polymorphisms in Antiplatelet Therapy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers